Warfarin anticoagulation and outcomes in patients with atrial fibrillation - A systematic review and metaanalysis

被引:206
|
作者
Reynolds, MW
Fahrbach, K
Hauch, O
Wygant, G
Estok, R
Cella, C
Nalysnyk, L
机构
[1] MetaWorks Inc, Medford, MA USA
[2] AstraZeneca LP, Wilmington, DE USA
关键词
anticoagulation; atrial fibrillation; warfarin;
D O I
10.1378/chest.126.6.1938
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To examine the relationship between international normalized ratio (INR) and Outcomes (major bleeding events and strokes) in patients with atrial fibrillation (AF) receiving anticoagulation with warfarin. Methods: A systematic review and metaanalysis of studies published in the English language between January 1, 1985, and October 30, 2002, was performed. MEDLINE (PubMed), Current Contents, and relevant reference lists were searched. Studies enrolling patients with nonvalvular AF receiving warfarin anticoagulation were eligible for inclusion if they reported stroke and/or major bleeding events in relation to INR, or time spent in therapeutic range. The risk of bleeds in overanticoagulated patients (INR > 3) and the risk of strokes in underanticoagulated patients (INR < 2) were assessed. Results: Twenty-one studies (6,248 patients) met all inclusion criteria. Of the 21 studies, a target conventional INR of 2 to 3 was used in 9 studies. An INR < 2, compared with an INR : 2, was associated with an odds ratio (OR) for ischemic events of 5.07 (95% confidence interval [CI], 2.92 to 8.80). An INR > 3, compared with an INR :5 3, was associated with an OR for bleeding events of 3.21 (95% CI, 1.24 to 8.28). On average, in the four studies with a target INR range of 2 to 3, patients with AF receiving warfarin spent 61% of time within, 13% of time above, and 26% below the therapeutic range. Conclusion: Available evidence indicates that in patients with nonvalvular AF, the risk of ischemic stroke with insufficient warfarin anticoagulation (INR < 2), and the risk of bleeding events with overanticoagulation (INR > 3) are significantly higher relative to patients with AF maintained within the recommended INR of 2 to 3. However, the published data are sparse, heterogeneous, and primarily reported from clinical trials. More studies evaluating clinical outcomes in relation to INR are needed, especially in a real-world setting.
引用
收藏
页码:1938 / 1945
页数:8
相关论文
共 50 条
  • [31] Bridging anticoagulation for interruption of warfarin in a patient with atrial fibrillation
    Tseng, Eric
    Crowther, Mark A.
    Hillis, Christopher M.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2016, 188 (05) : 361 - 362
  • [32] The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation
    Budhraja, Vikram
    ANNALS OF INTERNAL MEDICINE, 2010, 152 (04) : 265 - 265
  • [33] Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation
    Hernandez, Inmaculada
    Zhang, Yuting
    Brooks, Maria M.
    Chin, Paul K. L.
    Saba, Samir
    STROKE, 2017, 48 (01) : 159 - +
  • [34] Comparison of benefit between dabigatran and warfarin among patients with atrial fibrillation: A systematic review
    Sulieman, Amal K.
    ARCHIVES OF PHARMACY PRACTICE, 2016, 7 (02) : 33 - 42
  • [35] Effect of access to anticoagulation management services on warfarin use in patients with atrial fibrillation
    Burkiewicz, JS
    PHARMACOTHERAPY, 2005, 25 (08): : 1062 - 1067
  • [36] Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease
    Yang, Felix
    Hellyer, Jessica A.
    Than, Claire
    Ullal, Aditya J.
    Kaiser, Daniel W.
    Heidenreich, Paul A.
    Hoang, Donald D.
    Winkelmayer, Wolfgang C.
    Schmitt, Susan
    Frayne, Susan M.
    Phibbs, Ciaran S.
    Turakhia, Mintu P.
    HEART, 2017, 103 (11) : 818 - 826
  • [37] A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation
    Bhavnani, M
    Shwe, KH
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (04) : 1110 - 1111
  • [38] Anticoagulation in Patients With Atrial Fibrillation After a Transcatheter Aortic Valve Replacement: A Systematic Review
    Galo, Jason
    Al Halban, Fahad
    Chambers, Sharde
    de Marchena, Eduardo
    Saint Croix, Garly Rushler
    Milford, Brett
    Olorunfemi, Odunayo
    CIRCULATION, 2019, 140
  • [39] Do Current Guidelines Result in Overuse of Warfarin Anticoagulation in Patients With Atrial Fibrillation?
    Hart, Robert G.
    Halperin, Jonathan L.
    ANNALS OF INTERNAL MEDICINE, 2009, 151 (05) : 355 - U83
  • [40] Warfarin therapy, anticoagulation intensity and outcomes in older vs. younger patients with atrial fibrillation: The ATRIA study
    Go, Alan S.
    Fang, Margaret C.
    Chang, Yuchiao
    Borowsky, Leila H.
    Pomernacki, Niela K.
    Singer, Daniel E.
    CIRCULATION, 2007, 116 (16) : 813 - 813